KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

30 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

14 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

07 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

05 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

23 Oct 2024 07:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

09 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 Aug 2024 11:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

19 Aug 2024 22:45:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering

19 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

31 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

08 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire